Table 7.
List of published p-PBPK models to predict fetal exposure.
| Compound | Species in which model was developed and validated | Software | References |
|---|---|---|---|
| Darunavir | Humans | Simcyp® | (72) |
| Dolutegravir | Humans | Berkeley Madonna | (40) |
| Dolutegravir | Humans-neonates | SimBiology® | (73) |
| Zidovudine, Theophylline | Humans | Simcyp®/ Matlab | (74) |
| Acetaminophen | Humans | Open Systems Pharmacology® | (75) |
| Nevirapine | Humans | R | (57) |
| Tenofovir, emtricitabine | Humans | Simcyp®, R | (65) |
| BDE-47 (polybrominated diphenyl ether) | Male, female (pregnant and non-pregnant rats) | ACSL® (Advanced Continuous Simulation Language) | (69) |
| Bisphenol A | Humans | R | (76) |
| Perfluorooctanoic acid (PFOA) and Perfluorooctane sulfate (PFOS) | Humans | ACSL® (Advanced Continuous Simulation Language) | (77) |
| Manganese | Humans | ACSL® (Advanced Continuous Simulation Language) | (78) |
| Thalidomide, Efavirenz | Humans | Simbiology® | (79) |
| Napthalene | Humans | CFD-PBPK | (80) |
| 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) | Pregnant female rats | ACSL® (Advanced Continuous Simulation Language) | (81) |